DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Deferoxamine
Deferoxamine
Trs
Tall Man Lettering List REPORT DECEMBER 2013 1
Depletion of Trace Elements and Acute Ocular Toxicity Induced by Desferrioxamine in Patients with Thalassaemia
Chelation Therapy
Cardiotoxicity of Doxorubicin Is Mediated Through Mitochondrial Iron Accumulation
Effect of Antioxidant Treatment of Streptozotocin-Induced Diabetic Rats on Endoneurial Blood Flow, Motor Nerve Conduction Veloci
Review of Oral Iron Chelators (Deferiprone and Deferasirox) for the Treatment of Iron Overload in Pediatric Patients
Iron Chelating Agents
Changes in Tissue Gadolinium Biodistribution Measured in an Animal Model Exposed to Four Chelating Agents
Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases
Estonian Statistics on Medicines 2016 1/41
Lipoic Acid Reduces Iron-Induced Toxicity and Oxidative Stress in a Model of Iron Overload
How I Treat Transfusional Iron Overload
World Health Organization Model List of Essential Medicines, 21St List, 2019
Comparison Between Deferoxamine and Deferiprone (L1) in Iron-Loaded Thalassemia Patients
Estonian Statistics on Medicines 2013 1/44
Iron Chelating Agents (Desferal Exjade Ferriprox Jadenu) C15214-A
Deferoxamine Mesylate
Top View
Package Leaflet: Information for the User
Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
021825Orig1s000
Exjade, INN-Deferasirox
Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2 ALICJA KUBAN-JANKOWSKA 1, KAMLESH K
Clinical Policy: Chelation Therapy Reference Number: HNCA.CP.MP
Use of Chelating Agents in Medicine
The Selection and Use of Essential Medicines
An Overview of Complications Associated with Deferoxamine Therapy in Thalassemia
Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-Based Case Report
The Cardioprotective Effect of Dexrazoxane (Cardioxane) Is Consistent with Sequestration of Poly(ADP-Ribose) by Self-Assembly and Not Depletion of Topoisomerase 2B
Iron Chelators
Elemental Speciation in Human Health Risk Assessment
Chelation Therapy for Non-Overload Conditions
©Ferrata Storti Foundation
CP.PHAR.147 Deferiprone (Ferriprox)
FERRIPROX Oral Solution Safely and Effectively
Deferoxamine B: a Natural, Excellent and Versatile Metal Chelator
“All Things Are Poison,” So What Should We Test For? Evaluation of Poisoning and Drug Overdose
Laboratory Procedure Manual: Biochemistry Profile
GU-1 Custom Topcoat
Chelation in Metal Intoxication
Effects of Iron, Copper, Cobalt, and Their Chelators on the Cytotoxicity of Bleomycin1
Chelation Therapy in the Treatment of Metal Intoxication Page Left Intentionally Blank Chelation Therapy in the Treatment of Metal Intoxication
A Fast and Validated Chromatographic Method for Simultaneous Determination of Deferoxamine and D- Penicillamine Via Chelate Form
Medical Policy
Plasma Copper and Antioxidant Status in Wilson's Disease
Review Article Rationale for the Successful Management of EDTA Chelation Therapy in Human Burden by Toxic Metals
Study Protocol
Drug-Induced Hyperpigmentation: Review and Case Series
Chelation Therapy in Intoxications with Mercury, Lead and Copper
EXJADE General
Chelation Therapy for Non-Overload Conditions
Cardiotoxicity
Chelating Agents Pa Summary
Chelation Therapy Effective Date: 2/1/17
Chelation for Autism Spectrum Disorder (ASD) (Review)
Iron Chelators in Reducing Serum Ferritin Level in Thalassemia Major: a Randomized Trial
Alpha-Lipoic Acid Attenuates Iron Overload- Induced Structural Changes in the Liver of the Laboratory Mouse (Mus Musculus)
Appendix C - Guidelines for IV Medication Administration
Transdermal Deferoxamine Prevents Pressure-Induced Diabetic Ulcers
HSDB Home > HSDB Search Results > Full Record
The Selection and Use of Essential Medicines
Chelation Therapy The801.008 Coverage
Methods in Literature-Based Drug Discovery
Deferoxamine Mesylate Policy Number: IEXD0206.01 Effective Date: January 1, 2021 Instructions for Use
Evaluation of Protective and Curative Role of Α-Lipoic Acid and Selenium in Gentamicin-Induced Nephrotoxicity in Rabbits
Resolution Ap (2000) 1
Desferal (Deferoxamine Mesylate)
The Selection and Use of Essential Medicines
Efficacy and Safety of Iron-Chelation Therapy With
Deferoxamine Protective Effect in Preventing Nephrotoxicity in Children Under Treatment with Doxorubicin: a Randomized Clinical Trial
Part B Coverage Categories